{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:08Z","timestamp":1785491888049,"version":"3.56.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary oral vancomycin prophylaxis has been reported to reduce rates of recurrent Clostridioides difficile infection (CDI) in adult patients, but there are limited data in pediatrics. This study sought to assess the impact of secondary oral vancomycin prophylaxis (OVP) during broad-spectrum antibiotic administration in reducing CDI in children and young adults with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of children and young adults with cancer with primary CDI episode treated from 2017 to 2024. To determine the causal impact of secondary oral vancomycin prophylaxis during antibiotic administration to prevent CDI in the 6 months after the primary episode, propensity score matching and weighted generalized estimating equations were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial cohort included 163 patients who experienced primary CDI. After exclusions, 72 patients received 150 courses of broad-spectrum antibiotics within 6 months following their initial infection. Fifteen patients received 27 episodes of OVP. CDIs were not significantly decreased, occurring in 22 of 123 (17.9%) courses in patients who did not receive OVP and 2 of 27 (7.4%) in courses with prophylaxis. Propensity score matching resulted in 49 broad-spectrum antibiotic episodes from 19 patients, forming 11 matched sets. Receipt of OVP was significantly associated with reduced risk of CDI (adjusted odds ratio, 0.074 [95% confidence interval, .01\u2013.54]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center retrospective study of children and young adults with cancer with primary CDI, receipt of OVP was significantly associated with reduced risk of CDI recurrence when receiving broad-spectrum antibiotic therapy. Given the small sample size and likely residual confounding, these findings should be considered hypothesis-generating pending confirmation in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag365","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:34:39Z","timestamp":1781613279000},"source":"Crossref","is-referenced-by-count":0,"title":["Secondary Oral Vancomycin Prophylaxis and\n                    <i>Clostridioides difficile<\/i>\n                    Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"given":"Isabela","family":"DeJohn","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4942-0044","authenticated-orcid":false,"given":"Caitlin","family":"Brammer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mysorewala","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Courter","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]},{"name":"Division of Pharmacy, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8849-6628","authenticated-orcid":false,"given":"Justin","family":"Markham","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]},{"name":"Division of Pharmacy, Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5274-5674","authenticated-orcid":false,"given":"Soumya","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-6513","authenticated-orcid":false,"given":"Grant","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5221","authenticated-orcid":false,"given":"Lara","family":"Danziger-Isakov","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7959-1445","authenticated-orcid":false,"given":"William R","family":"Otto","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center , Cincinnati Ohio ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"2026073105064484100_ofag365-B1","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.eclinm.2024.102604","article-title":"Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update","volume":"72","author":"Patel","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026073105064484100_ofag365-B2","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/jpids\/piab078","article-title":"Epidemiology, diagnosis, and treatment of Clostridioides difficile infection in immunocompromised children","volume":"10","author":"Cross","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2026073105064484100_ofag365-B3","doi-asserted-by":"crossref","first-page":"e2023062307","DOI":"10.1542\/peds.2023-062307","article-title":"Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy","volume":"152","author":"Shirley","year":"2023","journal-title":"Pediatrics"},{"key":"2026073105064484100_ofag365-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpeds.2022.08.030","article-title":"Clostridioides difficile infection in hospitalized pediatric patients: comparisons of epidemiology, testing, and treatment from 2013 to 2019","volume":"252","author":"Edwards","year":"2023","journal-title":"J Pediatr"},{"key":"2026073105064484100_ofag365-B5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jpeds.2013.01.062","article-title":"Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer","volume":"163","author":"de Blank","year":"2013","journal-title":"J Pediatr"},{"key":"2026073105064484100_ofag365-B6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/jpids\/piaa090","article-title":"Clostridioides difficile infections in inpatient pediatric oncology patients: a cohort study evaluating risk factors and associated outcomes","volume":"10","author":"Willis","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2026073105064484100_ofag365-B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/INF.0b013e31820970d1","article-title":"Clostridium difficile infection among children with cancer","volume":"30","author":"Tai","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2026073105064484100_ofag365-B8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/INF.0000000000003126","article-title":"Epidemiologic and clinical characteristics of Clostridioides difficile infections in hospitalized and outpatient pediatric oncology and hematopoietic stem cell transplant patients","volume":"40","author":"Barbar","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2026073105064484100_ofag365-B9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MPH.0000000000001411","article-title":"Intensity of therapy for malignancy and risk for recurrent and complicated Clostridium difficile infection in children","volume":"41","author":"Willis","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026073105064484100_ofag365-B10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1001\/jama.2025.18089","article-title":"Recurrent Clostridioides difficile infections","volume":"334","author":"van Prehn","year":"2025","journal-title":"JAMA"},{"key":"2026073105064484100_ofag365-B11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026073105064484100_ofag365-B12","doi-asserted-by":"crossref","first-page":"e2517834","DOI":"10.1001\/jamanetworkopen.2025.17834","article-title":"Oral vancomycin for prevention of recurrent Clostridioides difficile infection","volume":"8","author":"Keating","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026073105064484100_ofag365-B13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026073105064484100_ofag365-B14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026073105064484100_ofag365-B15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026073105064484100_ofag365-B16","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026073105064484100_ofag365-B17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026073105064484100_ofag365-B18","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1093\/jpids\/piu121","article-title":"Concomitant medical conditions and therapies preclude accurate classification of children with severe or severe complicated Clostridium difficile infection","volume":"4","author":"Kociolek","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2026073105064484100_ofag365-B19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1017\/ice.2017.94","article-title":"Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals","volume":"38","author":"Gerber","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026073105064484100_ofag365-B20","doi-asserted-by":"crossref","first-page":"ofac492.459","DOI":"10.1093\/ofid\/ofac492.459","article-title":"Antibiotic spectrum index and risk of Clostridioides difficile infection","volume":"9","author":"Ray","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026073105064484100_ofag365-B21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026073105064484100_ofag365-B22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1198\/106186006X137047","article-title":"Optimal full matching and related designs via network flows","volume":"15","author":"Hansen","year":"2006","journal-title":"J Comput Graph Stat"},{"key":"2026073105064484100_ofag365-B23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000004178","article-title":"Increased prevalence of Clostridioides difficile infection among pediatric oncology patients: risk factors for infection and complications","volume":"43","author":"Murphy","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2026073105064484100_ofag365-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.05.001","article-title":"Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients","volume":"171","author":"Haeusler","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026073105064484100_ofag365-B25","doi-asserted-by":"crossref","first-page":"e2020031807","DOI":"10.1542\/peds.2020-031807","article-title":"Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection","volume":"148","author":"Bao","year":"2021","journal-title":"Pediatrics"},{"key":"2026073105064484100_ofag365-B26","doi-asserted-by":"crossref","first-page":"ofag149","DOI":"10.1093\/ofid\/ofag149","article-title":"Clostridioides difficile colonization and infection in pediatric oncology and stem cell transplant patients","volume":"13","author":"Willis","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026073105064484100_ofag365-B27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1017\/ice.2023.18","article-title":"Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 update","volume":"44","author":"Kociolek","year":"2023","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026073105064484100_ofag365-B28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/cid\/civ432","article-title":"Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study","volume":"61","author":"Freedberg","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026073105064484100_ofag365-B29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkw383","article-title":"Short- and long-term effects of oral vancomycin on the human intestinal microbiota","volume":"72","author":"Isaac","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026073105064484100_ofag365-B30","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile\u2013associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag365\/68563174\/ofag365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag365\/68563174\/ofag365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag365\/68563174\/ofag365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:06:51Z","timestamp":1785488811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag365\/8712147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag365","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,20]]},"article-number":"ofag365"}}